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A major paradigm shift in cancer biology
has involved the realization that cancers
are not just clonal populations of cells
gone awry, but rather are complex multi-
cellular tissues in which individual cells
respond to intercellular signals, the
microenvironment, and the therapies
directed against them. A driving force for
this shift has been the emergence of
angiogenesis as a critical factor in can-
cer progression, from the initial develop-
ment of a vascularized primary tumor,
which is no longer limited by the diffusion
of O2 from host vessels, to the establish-
ment of metastases, which define the
terminal stage of the disease.
The importance of the tumor
microenvironment in determining clinical
outcome was highlighted by Gray et al.
(1953), who proposed that hypoxic can-
cer cells are resistant to radiation therapy.
The effect of hypoxia was interpreted as
reflecting the requirement for O2 as a
source of radiation-induced radicals that
mediate tumor cell killing. The more gen-
eral principle, which was not appreciated
at the time, is that hypoxia is an important
selective force in the progression of many
cancers (reviewed in Semenza, 2003).
The discovery of radiation resistance
of hypoxic cells was followed decades
later by the demonstration that hypoxia is
the principal physiologic stimulus for
angiogenesis and, subsequently, by the
discovery of hypoxia-inducible factor 1
(HIF-1) as the major transcriptional regu-
lator of hypoxia-induced angiogenesis
through transactivation of genes encod-
ing multiple angiogenic growth factors
including vascular endothelial growth
factor (VEGF) (reviewed in Semenza,
2003). An important connection between
radiation and angiogenesis was made by
the demonstration that the tumor vascu-
lature represents an important target of
radiation therapy and a major determi-
nant of the clinical response (Garcia-
Barros et al., 2003).
Clinical and preclinical studies have
also implicated HIF-1 in radiation resis-
tance. In patients with oropharyngeal
cancer, overexpression of HIF-1α in
tumor biopsy is associated with an
increased risk of failure to achieve com-
plete remission after radiation therapy
(Aebersold et al., 2001). Conversely,
tumor xenografts of HIF-1α null trans-
formed mouse embryo fibroblasts mani-
fest increased radiation sensitivity
(Unruh et al., 2003).
An elegant study by Moeller et al.
(2004) in this issue of Cancer Cell further
establishes the connection between HIF-
1, tumor vasculature, and radiation resis-
tance. The authors demonstrate that
irradiation of tumor xenografts induces
HIF-1 activity, leading to the expression
of VEGF and basic fibroblast growth fac-
tor (bFGF), which act to prevent radia-
tion-induced endothelial cell (EC) death
(Figure 1). Remarkably, the induction of
HIF-1 does not start until 12 hr and
peaks at 48 hr after radiation. Moeller et
al. (2004) provide evidence that radia-
tion-induced reoxygenation of hypoxic
tumor cells results in the production of
reactive oxygen species (ROS) that
induce HIF-1 activity, as determined by
the expression of green fluorescent pro-
tein (GFP) driven by a promoter contain-
ing a hypoxia response element (HRE).
How do ROS generated during
reoxygenation induce HIF-1 activity? The
half-life and transcriptional activity of
HIF-1α are negatively regulated by O2-
dependent prolyl and asparaginyl
hydroxylation, respectively (reviewed in
Semenza, 2003). During the hydroxyla-
tion reactions, Fe (II) in the active site of
the hydroxylases is oxidized to Fe (III).
The hydroxylases utilize ascorbate as a
cofactor to reduce Fe (III) back to Fe (II).
Thus, hydroxylase activity may be inhibit-
ed as a result of ROS-mediated deple-
tion of ascorbate.
Moeller et al. (2004) demonstrate
that administration of the free radical
scavenger AEOL-10113 blocks the
induction of HIF-1 activity and results in
dramatic regression of the tumor vascu-
lature and a significant enhancement of
tumor growth delay. Ascorbate adminis-
tration has been shown to inhibit HIF-1α
expression in cancer cells ex vivo
(Knowles et al., 2003). Could ascorbate
administration to patients potentiate the
effects of radiation by blocking induction
of HIF-1 and VEGF?
The authors also show that treatment
of tumor-bearing mice with YC-1, which is
a small-molecule inhibitor of HIF-1 (Yeo
et al., 2003), impairs tumor growth after a
dose of radiation (10 Gy) that alone had
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Failure to achieve complete remission after radiation therapy is a predictor of patient mortality, and hypoxic cancer cells
are more likely to survive radiation therapy. Recent studies have shown that radiation-induced endothelial cell death
results in secondary tumor cell killing. In this issue of Cancer Cell, Moeller et al. (2004) now provide evidence that radiation
induces HIF-1-mediated expression of VEGF and bFGF in tumor cells, which promotes endothelial cell survival.
Figure 1. Radiation induces HIF-1 activity and
production of survival factors
Radiation therapy (RT) results in the reoxy-
genation of hypoxic tumor cells and the pro-
duction of reactive oxygen species (ROS)
that induce the activity of hypoxia-inducible
factor 1 (HIF-1), which directly activates tran-
scription of the VEGF gene encoding vascu-
lar endothelial growth factor. Expression of
basic fibroblast growth factor (bFGF) is also
induced in a HIF-1-dependent manner by
unknown mechanisms. The secretion of
VEGF and bFGF by tumor cells promotes
endothelial cell (EC) survival. Maintenance
of a functional vasculature increases the sur-
vival of tumor cells. Thus, to the extent that
radiation-induced EC death contributes to
secondary tumor cell killing, activation of the
HIF-1 response pathway may contribute to
radiation resistance. The response can be
blocked by the administration of either
AEOL-10113, a superoxide dismutase mimet-
ic, or YC-1, a small molecule inhibitor of HIF-1.
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little effect on tumor growth.The results of
treatment with AEOL-10113 or YC-1 after
radiation therapy have potentially impor-
tant clinical implications. Further studies
are required to determine whether this
sort of sequential therapy at higher doses
can have synergistic effects leading to
tumor ablation.
Finally, the authors demonstrate that
reoxygenation of cultured cells following
hypoxia results in a dramatic increase in
GFP activity compared to hypoxia alone.
They provide evidence that this is related
to the hypoxia-induced formation of
stress granules, which sequester mRNAs
transcribed by HIF-1 and prevent their
translation until reoxygenation occurs.
This result is in contrast to many studies
that have demonstrated increased
activity of HRE-driven luciferase reporter
genes and increased secretion of
endogenous VEGF protein by tumor cell
lines exposed to continuous hypoxia. The
presence of an internal ribosomal entry
site, which allows cap-independent trans-
lation, is a feature of the mRNAs encod-
ing HIF-1α, VEGF, and possibly other
hypoxia-inducible gene products (Stein et
al., 1998). Thus, there may be two cate-
gories of hypoxia-inducible gene prod-
ucts, those that are translated during
hypoxia and those that are not translated
until reoxygenation.
The combination of mechanistic
insight into fundamental aspects of can-
cer biology and the potential therapeutic
implications makes this a remarkable
paper. One factor that may limit the
extent to which these results are applica-
ble to human cancers is that the data
were derived from tumor xenografts.
Recent studies suggest that the vascula-
ture of tumor xenografts differs signifi-
cantly from the vasculature of
spontaneously arising tumors (Ruzinova
et al., 2003). Subcutaneous injection of
cancer cells into nude mice results in the
rapid growth of a tumor, the vasculariza-
tion of which is dependent upon the
recruitment of bone marrow-derived
endothelial progenitor cells. In contrast,
the vasculature of slower-growing spon-
taneous tumors may occur primarily via
the process of angiogenesis, in which
new capillaries bud from existing host
vessels and grow into the tumor. Thus, it
will be important to replicate the findings
of Moeller et al. (2004) in a spontaneous
tumor model.
The results reported by Moeller et al.
(2004) represent an important advance
linking intratumoral hypoxia, HIF-1, EC
survival, and radiation resistance. Like all
good studies, their work generates many
provocative questions. Further studies
will determine the extent to which these
intriguing observations are relevant to
cancer patients and their treatment.
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The Trojan horse was as a clever instru-
ment of war used by the Greeks to
deceive the Trojans. Epic accounts have it
that the Greeks built a giant hollow wood-
en horse—loaded with armed soldiers—
which was delivered as a gift offering of
peace.The strategy worked when the sol-
diers quietly climbed down from the horse
and opened the city gates, thus providing
for access to and defeat of Troy after a
decade of siege by the Greek army. In
spite of its overuse (a Google search
reveals over 1.1 × 106 hits), this ancient
military analogy can perhaps be best
used to describe an antitumor approach
Engineered embryonic endothelial progenitor cells as therapeutic
Trojan horses
While the hematogenic contribution of circulating endothelial cells to tumor angiogenesis is not entirely understood, one
can exploit this phenomenon as a therapeutic strategy. In this issue of Cancer Cell, Wei et al. (2004) show that murine
embryonic endothelial progenitor cells preferentially home to sites of lung metastases, evade immunological rejection, and
can exert a bystander antitumor effect when modified to contain a suicide gene construct that activates a prodrug.
Treatment with the prodrug led to improved survival in syngeneic and nonsyngeneic tumor-bearing mouse models. The
conceptual advance put forward by this study might result in translational applications.
